Lipocine INC 8-K filings

Lipocine Inc. will present Phase 2 data on its drug candidate LPCN 2401 at the Obesity Societys Annual ObesityWeek conference in November.

Lipocine Inc. will present at the H.C. Wainwright 26th Annual Global Investor Conference on September 9, 2024, to discuss its biopharmaceutical pipeline.

Lipocine reported positive clinical trial results for multiple drug candidates and improved financial performance for the second quarter of 2024.

Lipocine Inc. filed an amendment to its original 8-K report to disclose the Board of Directors' decision to hold annual advisory votes on executive compensation, following a stockholder vote.

Lipocine's oral brexanolone, LPCN 1154, demonstrated bioequivalence to intravenous brexanolone in a pivotal pharmacokinetic study, supporting a planned NDA submission.

Lipocine announced positive 52-week results from its Phase 2 study of LPCN 1148 for treating cirrhosis, showing improvements in sarcopenia and hepatic encephalopathy.

Lipocine Inc. held its annual general meeting on June 5, 2024, where shareholders voted on the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the stock incentive plan.

Lipocine Inc.'s Board of Directors has approved a cash bonus plan for employees and amended its stock incentive plan to remove language allowing for repricing of underwater stock options without shareholder approval.

Lipocine announced a profitable first quarter of 2024, driven by a significant licensing agreement and positive clinical trial results across multiple drug candidates.

Lipocine Inc. will present Phase 2 study data for LPCN 1148, an oral treatment for decompensated cirrhosis, at the European Association for the Study of the Liver (EASL) Congress in June.

Lipocine has completed dosing in its pivotal study for LPCN 1154, an oral treatment for postpartum depression, with topline results expected late in the second quarter of 2024.

Lipocine Inc. has updated its corporate presentation for use in meetings with investors and analysts.

Lipocine Inc. has entered into a new sales agreement with A.G.P./Alliance Global Partners for an at-the-market offering of up to $10.6 million in common stock, while terminating a previous agreement with Cantor Fitzgerald & Co.

Lipocine's LPCN 2401 demonstrated statistically significant improvements in body composition, including increased lean mass and decreased fat mass, in a Phase 2 clinical trial for obesity management.

Lipocine's LPCN 1148 demonstrated positive topline results in a Phase 2 study for cirrhosis patients, showing improvements in muscle mass and reduced hepatic encephalopathy events.

Lipocine has completed enrollment and dosed the first cohort in a pivotal pharmacokinetic study of LPCN 1154, an oral brexanolone, for the treatment of postpartum depression, with topline results expected late in the second quarter of 2024.

Lipocine Inc. has updated its corporate presentation for use in meetings with investors and analysts.

Lipocine reported its full year 2023 financial results, highlighted by progress in clinical trials for LPCN 1154 and LPCN 1148, and a licensing agreement for TLANDO.

Lipocine Inc. will present at the 36th Annual Roth Conference on March 18, 2024, to discuss their CNS disorder treatments and meet with investors.

Lipocine has confirmed the 48-hour dosing regimen for its pivotal study of LPCN 1154, an oral treatment for postpartum depression, and is on track for topline results in Q2 2024.

Lipocine has granted Verity Pharma exclusive rights to commercialize TLANDO in the U.S. and Canada, receiving an upfront payment of $11 million and potential future milestone and royalty payments.